Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Tuberculosis

  Free Subscription


Articles published in J Antimicrob Chemother

Retrieve available abstracts of 18 articles:
HTML format



Single Articles


    March 2024
  1. YUNIVITA V, Gafar F, Santoso P, Chaidir L, et al
    Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.
    J Antimicrob Chemother. 2024 Mar 9:dkae057. doi: 10.1093.
    PubMed     Abstract available


    December 2023
  2. COMBRINCK J, Tshavhungwe P, Rohlwink U, Enslin N, et al
    Rifampicin and protein concentrations in paired spinal versus ventricular cerebrospinal fluid samples of children with tuberculous meningitis.
    J Antimicrob Chemother. 2023 Dec 15:dkad371. doi: 10.1093.
    PubMed     Abstract available


    September 2023
  3. MOK S, Roycroft E, Flanagan PR, Wagener J, et al
    Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.
    J Antimicrob Chemother. 2023 Sep 23:dkad252. doi: 10.1093.
    PubMed     Abstract available


    February 2023
  4. GUMBO T, Srivastava S, Deshpande D, Pasipanodya JG, et al
    Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development.
    J Antimicrob Chemother. 2023 Feb 16:dkad029. doi: 10.1093.
    PubMed     Abstract available


    June 2022
  5. GAUSI K, Chirehwa M, Ignatius EH, Court R, et al
    Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.
    J Antimicrob Chemother. 2022 Jun 9. pii: 6604654. doi: 10.1093.
    PubMed     Abstract available


    April 2022
  6. LOPEZ-VARELA E, Abulfathi AA, Strydom N, Goussard P, et al
    Drug concentration at the site of disease in children with pulmonary tuberculosis.
    J Antimicrob Chemother. 2022 Apr 25. pii: 6573919. doi: 10.1093.
    PubMed     Abstract available


    March 2022
  7. MUDDE SE, Upton AM, Lenaerts A, Bax HI, et al
    Delamanid or pretomanid? A Solomonic judgement!
    J Antimicrob Chemother. 2022;77:880-902.
    PubMed     Abstract available


  8. BATESON A, Ortiz Canseco J, McHugh TD, Witney AA, et al
    Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid.
    J Antimicrob Chemother. 2022 Mar 9. pii: 6544883. doi: 10.1093.
    PubMed     Abstract available


  9. UPTON CM, Steele CI, Maartens G, Diacon AH, et al
    Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB).
    J Antimicrob Chemother. 2022 Mar 8. pii: 6543975. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  10. WASSERMAN S, Brust JCM, Abdelwahab MT, Little F, et al
    Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study.
    J Antimicrob Chemother. 2022 Feb 2. pii: 6520540. doi: 10.1093.
    PubMed     Abstract available


    January 2022
  11. KIESWETTER NS, Ozturk M, Hlaka L, Chia JE, et al
    Intranasally administered S-MGB-364 displays antitubercular activity and modulates the host immune response to Mycobacterium tuberculosis infection.
    J Antimicrob Chemother. 2022 Jan 25. pii: 6515318. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  12. CHEUNG CY, McNeil MB, Cook GM
    Utilization of CRISPR interference to investigate the contribution of genes to pathogenesis in a macrophage model of Mycobacterium tuberculosis infection.
    J Antimicrob Chemother. 2021 Nov 28. pii: 6445137. doi: 10.1093.
    PubMed     Abstract available


    October 2021
  13. SUNDELL J, Bienvenu E, Abelo A, Ashton M, et al
    Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV.
    J Antimicrob Chemother. 2021;76:2950-2957.
    PubMed     Abstract available


    February 2021
  14. RAWIZZA HE, Oladokun R, Ejeliogu E, Oguche S, et al
    Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART.
    J Antimicrob Chemother. 2021;76:710-717.
    PubMed     Abstract available


    December 2020
  15. ALGHAMDI WA, Al-Shaer MH, Kipiani M, Barbakadze K, et al
    Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.
    J Antimicrob Chemother. 2020 Dec 30. pii: 6055881. doi: 10.1093.
    PubMed     Abstract available


  16. WEINER M, Gelfond J, Johnson-Pais TL, Engle M, et al
    Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis.
    J Antimicrob Chemother. 2020 Dec 29. pii: 6055076. doi: 10.1093.
    PubMed     Abstract available


  17. BLACKMAN A, Morrison B, Maruri F, van der Heijden Y, et al
    Re-evaluation of a novel resistance mutation in eccC5 of the ESX-5 secretion system in ofloxacin-resistant Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2020 Dec 23. pii: 6046147. doi: 10.1093.
    PubMed    


  18. TAHSEEN S, vanDeun A, de Jong BC, Decroo T, et al
    Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?
    J Antimicrob Chemother. 2020 Dec 1. pii: 6015577. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.